Aposense teams with GlaxoSmithKline
Article Thumbnail ImageJune 8, 2009 -- Molecular imaging and therapy developer Aposense of Petach-Tikva, Israel, is collaborating with British pharmaceutical firm GlaxoSmithKline (GSK) to evaluate the potential of Aposense's ML-10 PET tracer in monitoring drug activity in clinical studies of cancer therapies.
Member Sign In:
MemberID or E-mail Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  


The project is intended to assess ML-10's contribution in accelerating clinical development of cancer therapies. The initial term of the nonexclusive collaboration with GSK is for two years and can be extended on certain conditions. Financial terms were not disclosed.

Related Reading

Aposense begins trial, December 15, 2008

NeuroSurvival Technologies gets financing, changes name, August 20, 2008

IBA, NeuroSurvival Technologies partner, August 14, 2008

NST is cleared for Aposense trials, July 25, 2008

Copyright © 2009 AuntMinnie.com